Ocrevus (ocrelizumab)

drip
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card

We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Ocrevus (ocrelizumab)

How to buy Ocrevus: You can order Ocrevus (ocrelizumab) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Roche
Disease Multiple Sclerosis
Indication Relapsing or primary progressive forms of multiple sclerosis
Mode of Action Monoclonal antibody (immunotherapy)
Approval Status FDA approved (USA); TGA approved (AUS)
Strength 30 mg/mL

Who is ocrelizumab for?

Ocrevus (ocrelizumab) is indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis [1][4][5].

Recommended dose

Complete information about Ocrevus (ocrelizumab) dosage and administration can be found here: [1][4][5].
The standard dosage is:
  • Start dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion
  • Subsequent doses: 600 mg intravenous infusion every 6 months.
Patients should be monitored closely during and for at least one hour after infusion as infusion reactions may be possible. 
 
Consult your treating doctor for personalised dosing.

What is ocrelizumab and how does it work?

Ocrevus (ocrelizumab) is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis (MS) [1][4]. It is the first approved treatment for the primary progressive form of MS [2].
MS is a chronic, inflammatory, autoimmune disease that affects the central nervous system, and in particular the communication between the brain and other parts of the body [2]. The patient’s own immune system is supposed to be the cause of the damage to neurons [3]. In its relapsing form, MS is characterized by episodes of worsening function (relapses) which are initially followed by recovery periods (remissions). In its primary progressive form, MS is characterized by steadily worsening function from the onset of symptoms, often without early relapses or remissions [2].

The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to bind to a type of antigen, named CD20, found on the surface of some antibodies (pre-B and mature B lymphocytes) and induce their death [2]. In this way, it is supposed to prevent these antibodies from damaging neurons.

What is ocrelizumab's approval status?

Ocrevus (ocrelizumab) was approved by:
  • FDA (USA) on March 28, 2017
  • TGA (AUS) on July 13, 2017
  • EMA (EU) on January 11, 2017
for the treatment of adults with relapsing or primary progressive forms of multiple sclerosis [2][4][5].

The approval of Ocrevus (ocrelizumab) for relapsing forms of multiple sclerosis (RMS) was based on two randomized, double-blind clinical trials of identical design in patients with RMS who were treated for 96 weeks. In both studies, ocrelizumab was compared to another medicine for RMS named interferon beta-1a. In study 1, 410 patients received ocrelizumab and 411 received the interferon beta-1a, while in study 2 the distrubution of patients in the two groups was 417 and 418, respectively [1][4][5].
In both studies, the patients receiving ocrelizumab had reduced relapse rates and reduced worsening of disability compared to interferon beta-1a. Patients treated with ocrelizumab had a reduction in the annualized relapse rate of 46 % in study 1 and 47 % in study 2, with a proportion of relapse-free of 83 % (vs. 71% in the group treated with interferon beta-1a) in study 1, and 82 % (vs. 72 %) in study 2. The risk of disability progression was reduced by 40 % in the ocrelizumab arm. Disability progression was defined as an increase of 1.0 point or more from the baseline Expanded Disability Status Scale (EDSS) score for patients with baseline score of 5.5 or less, or 0.5 or more when the baseline score is greater than 5.5 at week 96. Moreover, the number of enlarged or new lesions was substantially less in the ocrelizumab group: the relative reduction of the mean number of new and/or enlarging lesions was around 95 % with one type of measure (T1 Gd-enhancing lesions) and about 80 % with another type of measure (new and/or enlarging T2 hyperintense lesions) [1][4][5].

The most common adverse reactions were upper respiratory tract infections and infusion reactions [1][4][5].

The approval of Ocrevus (ocrelizumab) for primary progressive multiple sclerosis (PPMS) was based on one randomized, double-blind clinical trial in which ocrelizumab (488 patients) was compared to placebo (244 patients).
The percentage of patients on ocrelizumab who had confirmed disability progression was 32.9 % versus 39.3 % of those on placebo, which accounts for a risk reduction of 24 %. Disability progression was defined as an increase of 1.0 point or more from the baseline Expanded Disability Status Scale (EDSS) score for patients with baseline score of 5.5 or less, or 0.5 or more when the baseline score is greater than 5.5. The mean change in the volume of lesions at week 120 was -0.39 with ocrelizumab and 0.79 with placebo [1][4][5].

The most common adverse reactions were upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections [1][4][5].
References
[1] Summary of Product Characteristics [FDA]: Ocrevus (ocrelizumab), Genentech, Mar. 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf
[2] FDA News Release: FDA approves new drug to treat multiple sclerosis, 29/09/2017.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549325.htm
[3] Wikipedia. Multiple sclerosis, (last update: 31/03/2017), cited on 19/05/21017.
https://en.wikipedia.org/wiki/Multiple_sclerosis
[4] Summary of Product Characteristics [TGA]: Ocrevus (ocrelizumab), Roche, July 2017.
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-02089-1
[5] Summary of Product Characteristics [EMA]: Ocrevus (ocrelizumab), Roche, Jan. 2018.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004043/WC500241124.pdf

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.

How can we help?

★ ★ ★ ★ ★
 
 

We've received requests for support from patients and doctors in over 120 countries, and delivered medicines to 6 continents. They've given us a 5 star rating for our service. Read what our friends from around the world are saying...

"My experience has been excellent. TheSocialMedwork were totally knowledgeable about the medicine I was looking for, and how to get it delivered to me quickly and easily. I UNCONDITIONALLY recommend TSM to anyone, it is truly a world-class organisation."

— Charles, USA

"During the transaction process I was very well informed by TheSocialMedwork team. They have put so much effort to ensure the best service was offered to me. Moreover the medicine I ordered was imported two weeks earlier. I highly recommend TheSocialMedwork."

— Tomasz, Poland

"I hope you know how needed you are and what it means to get a prompt, succinct and helpful reply. You are our hero. You have given us realistic hope in obtaining needed drugs in a timely way."

— Regina, US

"TheSocialMedwork were so helpful in getting the right medication to me, expediting its delivery, and keeping in touch. They simply can't do enough to help you. I would not hesitate to recommend TheSocialMedwork to anybody. Lovely people."

— Stephen, UK

"Totally awesome! Keep up the great work you're doing!"

— Dee, Australia

"When the doctor tells you that there are no treatments left to try, search further - there may be new treatments in other countries."

— Charlotte, The Netherlands

"TheSocialMedwork's professional capabilities, kindness and patience deserve our gratitude and respect."

— Haoyu, China

"My daughter died at the age of 21 because she couldn't get the treatment that might have saved her life. Now TheSocialMedwork might be able to help people like Abigail to get the best treatment."

— Frank, Virginia, USA

"The team is highly professional, friendly and will take care of everything. More options for doctor and patients. This service is transparent, unique and necessary. Keep it up!"

— Pa Tric, Germany

"Excellent communication and clarifications given every time when requested. They also provide fantastic support and updates from the start till the end of the process of the medicine provisioning."

— Milos, Serbia & Montenegro

Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM
Registered as a USA Delaware LLC.



Our service uses cookies.